AptarGroup, Inc. reported a net sales increase of 6% for the third quarter of 2025, reaching $961.1 million, compared to $909.3 million in the same period of 2024. The growth was attributed to a favorable currency translation impact of 4% and contributions from recent acquisitions, which added 1% to sales. Core sales, excluding these factors, saw a modest increase of 1%. The company's net income attributable to AptarGroup for the quarter was $127.9 million, up from $100.0 million year-over-year, resulting in diluted earnings per share of $1.92, compared to $1.48 in the prior year.
For the first nine months of 2025, AptarGroup's net sales totaled $2.81 billion, a 3% increase from $2.73 billion in the same period of 2024. The company experienced a similar 1% core sales growth when excluding the effects of acquisitions and currency fluctuations. The Aptar Pharma and Aptar Closures segments drove this growth, offsetting declines in tooling sales. Operating income for the nine-month period rose to $394.8 million from $376.4 million, reflecting effective cost management and increased sales volume.
Strategically, AptarGroup executed a significant acquisition by increasing its stake in BTY, a Chinese manufacturer, from 49% to 80% for $29.2 million, which resulted in a $26.5 million gain from the remeasurement of the previously held equity interest. Additionally, the company announced plans to acquire Sommaplast, a Brazilian provider of oral dosing packaging solutions, for approximately $30 million to $35 million, pending regulatory approvals. These acquisitions are expected to enhance Aptar's product offerings in the beauty and pharmaceutical sectors.
Operationally, the company reported a total employee headcount of approximately 6,000 as of September 30, 2025, reflecting ongoing investments in talent to support growth initiatives. The Aptar Pharma segment reported strong demand for its products, particularly in the prescription drug and injectables markets, while the Aptar Beauty segment faced challenges with lower sales in certain product categories. The company also noted a 2% increase in its total assets, which reached $5.1 billion, driven by higher inventories and accounts receivable.
Looking ahead, AptarGroup anticipates adjusted earnings per share for the fourth quarter of 2025 to be in the range of $1.20 to $1.28, based on an effective tax rate of 19.5% to 21.5%. The company plans to invest approximately $250 million to $270 million in capital expenditures for the year, reflecting its commitment to growth and innovation despite potential macroeconomic challenges.
About APTARGROUP, INC.
AptarGroup, Inc. is a global leader in drug and consumer product dosing, dispensing, and protection technologies, serving markets such as pharmaceuticals, beauty, food, and personal care. With a focus on innovation and sustainability, Aptar offers products like dispensing pumps and aerosol valves. The company targets diverse customers, including major brands, and is expanding through strategic acquisitions and digital health solutions, addressing growing market demands for convenience and eco-friendly packaging.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.